Department of Neurosurgery, The Sixth Affiliated Hospital of Nantong University, Yancheng, Jiangsu, China; Department of Neurosurgery, Yancheng Third People's Hospital, Yancheng, Jiangsu, China; Department of Neurosurgery, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, Jiangsu, China; Department of Neurosurgery, The Affiliated Yancheng Hospital of Southeast University, Yancheng, Jiangsu, China.
Department of Neurosurgery, The Sixth Affiliated Hospital of Nantong University, Yancheng, Jiangsu, China; Department of Neurosurgery, Yancheng Third People's Hospital, Yancheng, Jiangsu, China; Department of Neurosurgery, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, Jiangsu, China; Department of Neurosurgery, The Affiliated Yancheng Hospital of Southeast University, Yancheng, Jiangsu, China.
Gene. 2025 Jan 15;933:148963. doi: 10.1016/j.gene.2024.148963. Epub 2024 Sep 26.
There was evidence that ERP44 played vital roles in a variety of cancers. However, currently, ERP44 was rarely mentioned in gliomas. Therefore, we firstly integrated proteomics, bulk, as well as single-cell RNA-sequencing (scRNA-seq) to study the possible functions of ERP44 in glioma patients.
From online databases, we obtained bulk RNA-seq, scRNA-seq, and proteomic data of ERP44 in gliomas and verified the expression of ERP44 by qRT-PCR. Then, the Noman diagram, gene set enrichment analysis (GSEA), and univariate/multivariate Cox regression analysis were all carried out in turn. Further discussions were also conducted regarding tumor immunity and ERP44 expression.
ERP44 in glioma tissues was found to be considerably higher than that in normal tissues (P<0.05) in the TCGA dataset, as well as the verification of GSE50161, GSE4290, and qRT-PCR results. High ERP44 expression indicated poorer overall survival (OS) for glioma (P<0.05), and it might also be used to predict gliomas' OS independently (P<0.05). In order to estimate these patients' survival prognosis, a Noman chart was created with effectiveness. According to GSEA analysis, ERP44 might be implicated in five significant pathways in gliomas. The levels of immune cell infiltration of LGG, the tumor immune microenvironments, the immunological checkpoints of LGG, and GBM were all strongly linked with ERP44 in terms of tumor immunity (P<0.05). Further scRNA-seq analysis revealed that ERP44 could be expressed in various cell types, including T cells, Mono/Macrophages, and malignant cells.
ERP44 was an oncogenic gene in gliomas, serving as a bridge mediating prognosis and immunity.
有证据表明 ERP44 在多种癌症中发挥着重要作用。然而，目前在神经胶质瘤中很少提到 ERP44。因此，我们首先整合蛋白质组学、批量和单细胞 RNA 测序 (scRNA-seq) 来研究 ERP44 在神经胶质瘤患者中的可能作用。
我们从在线数据库中获得了 ERP44 在神经胶质瘤中的批量 RNA-seq、scRNA-seq 和蛋白质组学数据，并通过 qRT-PCR 验证了 ERP44 的表达。然后，依次进行了 Noman 图、基因集富集分析 (GSEA) 和单变量/多变量 Cox 回归分析。还进一步讨论了肿瘤免疫和 ERP44 表达。
在 TCGA 数据集以及 GSE50161、GSE4290 和 qRT-PCR 结果的验证中，我们发现神经胶质瘤组织中的 ERP44 明显高于正常组织 (P<0.05)。高 ERP44 表达表明神经胶质瘤的总生存期 (OS) 较差 (P<0.05)，并且它也可能独立用于预测神经胶质瘤的 OS (P<0.05)。为了估计这些患者的生存预后，我们创建了一个诺曼图来评估有效性。根据 GSEA 分析，ERP44 可能与神经胶质瘤中的五个重要途径有关。在肿瘤免疫方面，LGG 的免疫细胞浸润水平、肿瘤免疫微环境、LGG 和 GBM 的免疫检查点都与 ERP44 密切相关 (P<0.05)。进一步的 scRNA-seq 分析表明，ERP44 可以在包括 T 细胞、单核/巨噬细胞和恶性细胞在内的各种细胞类型中表达。
ERP44 是神经胶质瘤中的致癌基因，是连接预后和免疫的桥梁。
